Want to see IN:NATCAPSUQ full AI Analyst Report?
NATCAPSUQ Stock Chart & Stats
₹145.15
-₹1.02(-0.69%)
At close: 4:00 PM EDT
₹145.15
-₹1.02(-0.69%)
Day’s Range― - ―
52-Week Range₹135.60 - ₹296.40
Previous CloseN/A
Volume10.41K
Average Volume (3M)8.08K
Market Cap
₹1.49B
Enterprise Value₹2.74K
Total Cash (Recent Filing)₹53.75M
Total Debt (Recent Filing)₹1.12B
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.25
Shares Outstanding10,411,154
10 Day Avg. Volume870
30 Day Avg. Volume8,081
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.47
Price to Sales (P/S)0.55
P/FCF Ratio-9.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth in FY2026 shows the company can expand sales and capture demand; durable revenue expansion provides a base to restore margins and invest in efficiency, helping stabilize operations over the next several quarters if cost control follows.
Moderate LeverageDebt at roughly half of equity implies the balance sheet retains flexibility to access capital or refinance, lowering immediate solvency risk; moderate leverage gives management room to fund operational fixes or selective investments without extreme refinancing pressure.
Industry ExposureOperating in specialty and generic pharmaceuticals aligns the company with structurally stable demand for medications and recurring sales patterns; this sector exposure supports long-term revenue durability if the company retains product quality and market access.
Bears Say
Profitability DeteriorationA sharp swing to a sizable net loss and material margin compression undermines core earning power; sustained losses can erode cash, impede reinvestment, and force operational trade-offs, making a multi-quarter recovery necessary to re-establish a viable earnings base.
Weak Cash GenerationPersistently negative free cash flow and weak operating cash flow raise funding risk and reduce internal capacity to finance growth or cover losses; over months this can necessitate external financing, dilutive measures, or cuts to R&D and capex, constraining strategic flexibility.
Eroding Equity / Negative ROEDeclining equity and a negative ROE signal capital erosion from operating losses; if persistent, this weakens investor confidence, can increase cost of capital and limit options for non-dilutive funding, impairing the firm's ability to execute long-term strategies.
Natural Capsules Limited News
NATCAPSUQ FAQ
What was Natural Capsules Limited’s price range in the past 12 months?
Natural Capsules Limited lowest stock price was ₹135.60 and its highest was ₹296.40 in the past 12 months.
What is Natural Capsules Limited’s market cap?
Natural Capsules Limited’s market cap is ₹1.49B.
When is Natural Capsules Limited’s upcoming earnings report date?
Natural Capsules Limited’s upcoming earnings report date is Aug 12, 2026 which is in 5 days.
How were Natural Capsules Limited’s earnings last quarter?
Natural Capsules Limited released its earnings results on May 27, 2026. The company reported -₹3.317 earnings per share for the quarter, missing the consensus estimate of N/A by -₹3.317.
Is Natural Capsules Limited overvalued?
According to Wall Street analysts Natural Capsules Limited’s price is currently Overvalued.
Does Natural Capsules Limited pay dividends?
Natural Capsules Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Natural Capsules Limited dividends here
What is Natural Capsules Limited’s EPS estimate?
Natural Capsules Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Natural Capsules Limited have?
Natural Capsules Limited has 10,411,154 shares outstanding.
What happened to Natural Capsules Limited’s price movement after its last earnings report?
Natural Capsules Limited reported an EPS of -₹3.317 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.198%.
Which hedge fund is a major shareholder of Natural Capsules Limited?
Currently, no hedge funds are holding shares in IN:NATCAPSUQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Natural Capsules Limited
Natural Capsules Ltd. specializes in the production and global distribution of hard gelatin and cellulose capsule shells, catering to markets in India and abroad. The company offers a comprehensive array of capsule types, including those guaranteed free from bovine spongiform encephalopathy (BSE) and transmissible spongiform encephalopathy (TSE), shiny, sodium lauryl sulfate (SLS)-free, and halal-certified gelatin variants. Their product line further extends to fast-release, printed gelatin/cellulose, vegetarian, and enteric capsule shells. Beyond manufacturing shells, Natural Capsules Ltd. is also involved in formulating various pharmaceutical products in capsule dosage forms. Established in 1993, the company is headquartered in Bengaluru, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Alpa Laboratories Limited
―
Bafna Pharmaceuticals Limited
―
Bal Pharma Limited
―
Vaishali Pharma Ltd.
―